Related trials

ACCELERATE, 2015 - evacetrapib vs placebo

IMPROVE-IT, 2014 - ezetimibe vs control

dal-OUTCOMES, 2012 - dalcetrapib vs placebo

dal-VESSEL, 2011 - dalcetrapib vs placebo

AIM-HIGH, 2011 - niacin vs placebo (on top statin)

SEARCH, 2010 - simvastatin high dose vs simvastatin

ACCORD lipid, 2010 - fenofibrate vs placebo (on top simvastatine)

DEFINE, 2010 - anacetrapib vs placebo

SHARP, 2010 - ezetimibe+simvastatin vs placebo

ARBITER-HALTS 6, 2010 - ezetimibe vs niacin

ARBITER 2, 2009 - niacin vs placebo (on top statin)

Oxford Niaspan Study, 2009 - niacin vs placebo (on top statin)

Emmerich, 2009 - etofibrate vs placebo

ARBITER 6-HALTS (niacin vs ezetimibe), 2009 - niacin vs ezetimibe

SANDS, 2008 - aggressive treatment vs standard teatment

Tuttle, 2008 - low fat diet vs mediterranean-style diet

Guyton, 2008 - niacin+ezetimibe vs simvastatin+ezetimibe

GISSI-HF rosuvastatine, 2008 - rosuvastatin vs placebo

JUPITER, 2008 - rosuvastatin vs placebo

SAGE, 2007 - atorvastatin high dose vs pravastatin

RADIANCE 2, 2007 - torcetrapib vs placebo (on top of atorvastatin)

Krum, 2007 - rosuvastatin vs placebo

ILLUMINATE, 2007 - torcetrapib vs placebo (on top of atorvastatin)

CORONA, 2007 - rosuvastatin vs placebo

METEOR, 2007 - rosuvastatin vs placebo

Oxford Niaspan Study study, 2009	TRC10051
[NCT00232531]	download pdf: niacin | cholesterol lowering intervention for cardiovascular prevention

Treatments

Studied treatment	niacin 2g daily (added to statin therapy)
Control treatment	placebo (statins alone)
Concomittant treatment	statin therapy

Patients

Patients	patients with low HDL-C (
Inclusion criteria	1) HDL-C 50% stenosis of major epicardial vessel at angiography). There was no specific LDL-C inclusion criterion, but all patients were already taking statins
Exclusion criteria	contraindications to MRI or to NA (e.g., elevated liver enzymes or known intolerance); severe carotid stenosis (>70%); existing treatment with fibrates, nicorandil, or oral nitrates; recent acute coronary syndrome; uncontrolled diabetes; fasting triglyceride level >500 mg/dl; active peptic ulcer disease; and cardiac failure requiring diuretic treatment
Baseline characteristics	Male (%) 94%  Age (years) 65y  Diabetes (%) 64%

Method and design

Randomized effectives	35 / 36 (studied vs. control)
Design	Parallel groups
Blinding	double blind
Follow-up duration	1 year
Number of centre	single-center
Geographic area	USA
Hypothesis	Superiority
Primary endpoint	carotid artery wall area

Results

No results available for this trial - no clinical endpoint reported

Meta-analysis of all similar trials:

cholesterol lowering intervention in cardiovascular prevention for all chronical situations

HDL increasing drugs in cardiovascular prevention for all type of patients

niacin in cardiovascular prevention for all type of patients

Reference(s)

TrialResults-center ID	TRC10051
Trials register #	NCT00232531